Advertisement
| car t-cell therapy market: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| car t-cell therapy market: Cell and Gene Therapies Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard, 2018-11-27 In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee. |
| car t-cell therapy market: Immunopharmacogenomics Yusuke Nakamura, 2015-09-18 This book proposes immunogenomics, or immunopharmacogenomics, as the next-generation big science to uncover the role that the immune system plays in the pathogenesis of many diseases, by summarizing the importance of the deep sequencing of T-cell and B-cell receptors. Immunogenomics/immunopharmacogenomics, a genetic characterization of the immune system made possible by next-generation sequencing (NGS), will be important for the further understanding of the pathogenesis of various disease conditions. Abnormal immune responses in the body lead to development of autoimmune diseases and food allergies. Rejection of recipient cells and tissues, as well as severe immune reactions to donor cells, is also the result of uncontrolled immune responses in the recipient body. There have been many reports indicating that activated immune responses caused by the interaction of drugs and HLA are present in drug-induced skin hypersensitivity and liver toxicity. The importance of the host immune responses has been recognized in cancer treatments, not only for immunotherapy but also for cytotoxic agents and molecular targeted drugs. Hence, characterization of the T-cell receptor and B-cell receptor repertoire by means of NGS deep sequencing will ultimately make possible the identification of the molecular mechanisms that underlie various diseases and drug responses. In addition, this approach may contribute to the identification of antigens associated with the onset or progression of autoimmune diseases as well as food allergies. Although the germline alterations and somatic mutations have been extensively analyzed, changes or alterations of the immune responses during the course of various disease conditions or during various treatments have not been analyzed. It is also clear that computational analyses to draw meaningful inferences of functional recognition receptors on the immune cells remain a huge challenge. |
| car t-cell therapy market: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| car t-cell therapy market: Translational Regenerative Medicine Anthony Atala, Julie Allickson, 2014-12-01 Translational Regenerative Medicine is a reference book that outlines the life cycle for effective implementation of discoveries in the dynamic field of regenerative medicine. By addressing science, technology, development, regulatory, manufacturing, intellectual property, investment, financial, and clinical aspects of the field, this work takes a holistic look at the translation of science and disseminates knowledge for practical use of regenerative medicine tools, therapeutics, and diagnostics. Incorporating contributions from leaders in the fields of translational science across academia, industry, and government, this book establishes a more fluid transition for rapid translation of research to enhance human health and well-being. - Provides formulaic coverage of the landscape, process development, manufacturing, challenges, evaluation, and regulatory aspects of the most promising regenerative medicine clinical applications - Covers clinical aspects of regenerative medicine related to skin, cartilage, tendons, ligaments, joints, bone, fat, muscle, vascular system, hematopoietic /immune system, peripheral nerve, central nervous system, endocrine system, ophthalmic system, auditory system, oral system, respiratory system, cardiac system, renal system, hepatic system, gastrointestinal system, genitourinary system - Identifies effective, proven tools and metrics to identify and pursue clinical and commercial regenerative medicine |
| car t-cell therapy market: Blood and Marrow Transplant Handbook Richard T. Maziarz, Susan Schubach Slater, 2015-04-20 This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook includes indications for transplantation and donor selection, treatment guidelines for addressing complications during and after transplant, and recommendations for long-term follow up care. Concise, comprehensive, and easy-to-use, Blood and Marrow Transplant Handbook, 2nd Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers who care for transplant patients, and also residents, fellows, and other trainees. |
| car t-cell therapy market: Guidelines for Preparing Patent Landscape Reports World Intellectual Property Organization, 2015-08-24 These Guidelines are designed both for general users of patent information, as well as for those involved in producing Patent Landscape Reports (PLRs). They provide step-by-step instructions on how to prepare a PLR, as well as background information such as objectives, patent analytics, concepts and frameworks. |
| car t-cell therapy market: Gene and Cell Therapies Eve Hanna, Mondher Toumi, 2020-05-19 The major advances in the field of biotechnology and molecular biology in the twenty-first century have led to a better understanding of the pathophysiology of diseases. A new generation of biopharmaceuticals has emerged, including a wide and heterogeneous range of innovative cell and gene therapies. These therapies aim to prevent or treat chronic and serious life-threatening diseases, previously considered incurable. This book describes the evolution and adaptation of the regulatory environment to assess these therapies in contrast with the resistance of health technology assessment (HTA) agencies and payers to acknowledge the specificity of cell and gene therapies and the need to adapt existing decision-making frameworks. This book provides insights on the learnings from the experience of current cell and gene therapies (regulatory approval, HTA, and market access), in addition to future trends to enhance patient access to these therapies. Key Features: Describes the potential change of treatment paradigm and the specificity of cell and gene therapies, including the gradual move from repeated treatment administration to one-time single administration with the potential to be definite cure Highlights the challenges at the HTA level Discusses the affordability of future cell and gene therapies and the possible challenges for health insurance systems Provides potential solutions to address these challenges and ensure patient access to innovation while maintaining the sustainability of healthcare systems |
| car t-cell therapy market: Exploring Novel Clinical Trial Designs for Gene-Based Therapies National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Regenerative Medicine, 2020-08-27 Recognizing the potential design complexities and ethical issues associated with clinical trials for gene therapies, the Forum on Regenerative Medicine of the National Academies of Sciences, Engineering, and Medicine held a 1-day workshop in Washington, DC, on November 13, 2019. Speakers at the workshop discussed patient recruitment and selection for gene-based clinical trials, explored how the safety of new therapies is assessed, reviewed the challenges involving dose escalation, and spoke about ethical issues such as informed consent and the role of clinicians in recommending trials as options to their patients. The workshop also included discussions of topics related to gene therapies in the context of other available and potentially curative treatments, such as bone marrow transplantation for hemoglobinopathies. This publication summarizes the presentation and discussion of the workshop. |
| car t-cell therapy market: HIV-1 Latency Guido Silvestri, Mathias Lichterfeld, 2018-10-11 This volume summarizes recent advances in understanding the mechanisms of HIV-1 latency, in characterizing residual viral reservoirs, and in developing targeted interventions to reduce HIV-1 persistence during antiretroviral therapy. Specific chapters address the molecular mechanisms that govern and regulate HIV-1 transcription and latency; assays and technical approaches to quantify viral reservoirs in humans and animal models; the complex interchange between viral reservoirs and the host immune system; computational strategies to model viral reservoir dynamics; and the development of therapeutic approaches that target viral reservoir cells. With contributions from an interdisciplinary group of investigators that cover a broad spectrum of subjects, from molecular virology to proof-of-principle clinical trials, this book is a valuable resource for basic scientists, translational investigators, infectious-disease physicians, individuals living with HIV/AIDS and the general public. |
| car t-cell therapy market: Biologics, Biosimilars, and Biobetters Iqbal Ramzan, 2021-02-03 A comprehensive primer and reference, this book provides pharmacists and health practitioners the relevant science and policy concepts behind biologics, biosimilars, and biobetters from a practical and clinical perspective. Explains what pharmacists need to discuss the equivalence, efficacy, safety, and risks of biosimilars with physicians, health practitioners, and patients about Guides regulators on pragmatic approaches to dealing with these drugs in the context of rapidly evolving scientific and clinical evidence Balances scientific information on complex drugs with practical information, such as a checklist for pharmacists |
| car t-cell therapy market: Gene and Cellular Immunotherapy for Cancer Armin Ghobadi, John F. DiPersio, 2022-01-01 Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field. |
| car t-cell therapy market: Current Strategies in Cancer Gene Therapy Wolfgang Walther, 2017-01-17 This book describes important developments and emerging trends in experimental and clinical cancer gene therapy. It reflects the tremendous advances made over recent years with respect to immunogenes, suicide genes and gene correction therapies, as well as in gene suppression and miRNA therapies. Many of the described strategies focus on the generation of more efficient and specific means of attack at known and novel cellular targets associated with tumor development and progression. The book also details parallel improvements in vector design, vector delivery, and therapeutic efficacy. It offers readers a stimulating, broad overview of advances in the field, linking experimental strategies to their clinical applications. |
| car t-cell therapy market: Regulatory Aspects of Gene Therapy and Cell Therapy Products Maria Cristina Galli, Mercedes Serabian, 2015-09-15 This book discusses the different regulatory pathways for gene therapy (GT) and cell therapy (CT) medicinal products implemented by national and international bodies throughout the world (e.g. North and South America, Europe, and Asia). Each chapter, authored by experts from various regulatory bodies throughout the international community, walks the reader through the applications of nonclinical research to translational clinical research to licensure for these innovative products. More specifically, each chapter offers insights into fundamental considerations that are essential for developers of CT and GT products, in the areas of product manufacturing, pharmacology and toxicology, and clinical trial design, as well as pertinent must-know guidelines and regulations. Regulatory Aspects of Gene Therapy and Cell Therapy Products: A Global Perspective is part of the American Society of Gene and Cell Therapy sub-series of the highly successful Advances in Experimental Medicine and Biology series. It is essential reading for graduate students, clinicians, and researchers interested in gene and cell therapy and the regulation of pharmaceuticals. |
| car t-cell therapy market: Cell Therapy Adrian Gee, 2009-09-18 Cell Therapy: cGMP Facilities and Manufacturing is the source for a complete discussion of facility design and operation with practical approaches to a variety of day-to-day activities, such as staff training and competency, cleaning procedures, and environmental monitoring. This in-depth book also includes detailed reviews of quality, the framework of regulations, and professional standards. It meets a previously unmet need for a thorough facility-focused resource, Cell Therapy: cGMP Facilities and Manufacturing will be an important addition to the cell therapy professional’s library. Additional topics in Cell Therapy: cGMP Facilities and Manufacturing...Standard operating procedures - Supply management - Facility equipment - Product manufacturing, review, release and administration - Facility master file. |
| car t-cell therapy market: Praying for Emily Tom Whitehead, Kari Whitehead, Emily Whitehead, 2020-10-06 Discover the incredible true story of Emily Whitehead, the first child to receive CAR-T cell treatment for her leukemia -- and learn how her family's faith journey guided them in the fight for her life. When their five-year-old daughter was diagnosed with leukemia, Tom and Kari Whitehead's world was shattered. They vowed to do whatever it took to help their daughter, and as they made decisions about how to best treat her, Tom found his faith coming to him in whispers, guiding his decisions and keeping his hope alive, while Kari placed great faith in science and the doctors surrounding her little girl. But as Emily's condition continued to worsen, they both prayed for a miracle. Then, their miracle arrived, in the form of an experimental treatment called CAR-T cell therapy that, against all odds, saved Emily's life. Because of Emily's miraculous recovery, this treatment is now used widely to treat cancer and has gone on to save hundreds of lives and promises to help thousands more. For all the acclaim and attention this important new approach to treating cancer has received, few know the full story of all it took to make this miracle happen. In Praying for Emily, the Whiteheads share their story, recounting the belief, resilience, and support that got them through the most difficult time of their lives. |
| car t-cell therapy market: Ask a Manager Alison Green, 2018-05-01 From the creator of the popular website Ask a Manager and New York’s work-advice columnist comes a witty, practical guide to 200 difficult professional conversations—featuring all-new advice! There’s a reason Alison Green has been called “the Dear Abby of the work world.” Ten years as a workplace-advice columnist have taught her that people avoid awkward conversations in the office because they simply don’t know what to say. Thankfully, Green does—and in this incredibly helpful book, she tackles the tough discussions you may need to have during your career. You’ll learn what to say when • coworkers push their work on you—then take credit for it • you accidentally trash-talk someone in an email then hit “reply all” • you’re being micromanaged—or not being managed at all • you catch a colleague in a lie • your boss seems unhappy with your work • your cubemate’s loud speakerphone is making you homicidal • you got drunk at the holiday party Praise for Ask a Manager “A must-read for anyone who works . . . [Alison Green’s] advice boils down to the idea that you should be professional (even when others are not) and that communicating in a straightforward manner with candor and kindness will get you far, no matter where you work.”—Booklist (starred review) “The author’s friendly, warm, no-nonsense writing is a pleasure to read, and her advice can be widely applied to relationships in all areas of readers’ lives. Ideal for anyone new to the job market or new to management, or anyone hoping to improve their work experience.”—Library Journal (starred review) “I am a huge fan of Alison Green’s Ask a Manager column. This book is even better. It teaches us how to deal with many of the most vexing big and little problems in our workplaces—and to do so with grace, confidence, and a sense of humor.”—Robert Sutton, Stanford professor and author of The No Asshole Rule and The Asshole Survival Guide “Ask a Manager is the ultimate playbook for navigating the traditional workforce in a diplomatic but firm way.”—Erin Lowry, author of Broke Millennial: Stop Scraping By and Get Your Financial Life Together |
| car t-cell therapy market: Treatment of Leukemia and Lymphoma David A. Scheinberg, Joseph G. Jurcic, 2004-10-30 New Treatments of Leukemia and Lymphoma describes the most important advances in the therapy of hematopoietic cancers that have been derived from recent discoveries in cancer cell biology, kinase biochemistry, and immunology. Detailed descriptions of the large number of new and effective agents that have recently become available for the treatment of leukemias and lymphomas as well as an understanding of their mechanisms of action and their integration into current therapy are provided. A number of experimental drug reagents currently in clinical investigation are also discussed. The therapies include conventional anti-metabolites, monoclonal antibodies directed to cell surface receptors, antibodies tagged with toxins and radiopharmaceuticals, inhibitors of specific kinases, stem cell transplants, and engineered T-cells designed to selectively target hematopoietic cancers. The contents of the book will allow practitioners and investigators alike to understand what is current and state of the art as well as what to look for in the future.* Provides an up-to-date, state of the art discussion of a rapidly changing field * Great breadth covering conventional chemotherapeutic agents, biologic agents such as antibodies, novel small molecule inhibitors and genetically engineered cells * Written by international experts in each of the fields |
| car t-cell therapy market: Advances in Precision Medicine Oncology Hilal Arnouk, Bassam Abdul Rasool Hassan, 2021 Recent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such topics as ICIs and how they mount a robust immune response against cancer cells as well as the response of ICIs to treatment predictive biomarkers and their potential immune-related adverse events (irAEs). Additionally, the book includes a comprehensive review of the powerful FDA-approved therapeutic agent doxorubicin, highlighting the molecular mechanisms behind doxorubicin's drug resistance and critical side effects. |
| car t-cell therapy market: The Business of Healthcare Innovation Lawton Robert Burns, 2005-08-25 The Business of Healthcare Innovation is the first wide-ranging analysis of business trends in the manufacturing segment of the health care industry. In this leading edge volume, Professor Burns focuses on the key role of the 'producers' as the main source of innovation in health systems. Written by professors of the Wharton School and industry executives, this book provides a detailed overview of the pharmaceutical, biotechnology, genomics/proteomics, medical device and information technology sectors. It analyses the market structures of these sectors as well as the business models and corporate strategies of firms operating within them. Most importantly, the book describes the growing convergence between these sectors and the need for executives in one sector to increasingly draw upon trends in the others. It will be essential reading for students and researchers in the field of health management, and of great interest to strategy scholars, industry practitioners and management consultants. |
| car t-cell therapy market: Gene Therapy of Cancer Peter Walden, Uwe Trefzer, Wolfram Sterry, Farzin Farzaneh, 2012-12-06 The book provides a comprehensive overview of the current state, and the new concepts for the future directions of modern cancer therapy. Bringing together all the relevant aspects from basic and applied science, and the clinical experiences of this new direction in medicine, it is an up-to-date summary of the activities in the field and will be the basis for evaluating future progress in this area. |
| car t-cell therapy market: Adoptive Immunotherapy Burkhard Ludewig, Matthias W. Hoffmann, 2008-02-02 An authoritative collection of optimal techniques for producing and characterizing the immunologically active cells and effector molecules now gaining wide use in the clinical treatment of patients. Taking advantage of the latest technologies, the authors present readily reproducible experimental protocols for the study of dendritic cells, T cells, monoclonal antibodies, and bone marrow transplantation. The emphasis is on preclinicical and clinical applications and on the progress of selected approaches in clinical trials. Additional chapters cover the molecular definition of target antigens, mathematical modeling approaches to immunotherapy, and the utilization of regulatory T cells. The protocols make it possible to study the adoptive transfer of tailored antigen-specific immune cells and to improve the clinical application of adoptive immunotherapy. |
| car t-cell therapy market: Bioreactor Systems for Tissue Engineering Cornelia Kasper, Martijn van Griensven, Ralf Pörtner, 2009-02-03 The editors of this special volume would first like to thank all authors for their excellent contributions. We would also like to thank Prof. Dr. Thomas Scheper, Dr. Marion Hertel and Ulrike Kreusel for providing the opportunity to compose this volume and Springer for organizational and technical support. Tissue engineering represents one of the major emerging fields in modern b- technology; it combines different subjects ranging from biological and material sciences to engineering and clinical disciplines. The aim of tissue engineering is the development of therapeutic approaches to substitute diseased organs or tissues or improve their function. Therefore, three dimensional biocompatible materials are seeded with cells and cultivated in suitable systems to generate functional tissues. Many different aspects play a role in the formation of 3D tissue structures. In the first place the source of the used cells is of the utmost importance. To prevent tissue rejection or immune response, preferentially autologous cells are now used. In particular, stem cells from different sources are gaining exceptional importance as they can be differentiated into different tissues by using special media and supplements. In the field of biomaterials, numerous scaffold materials already exist but new composites are also being developed based on polymeric, natural or xenogenic sources. Moreover, a very important issue in tissue en- neering is the formation of tissues under well defined, controlled and reprod- ible conditions. Therefore, a substantial number of new bioreactors have been developed. |
| car t-cell therapy market: Ending Medical Reversal Vinayak K. Prasad, Adam S. Cifu, 2019-05-14 Why medicine adopts ineffective or harmful medical practices only to abandon them—sometimes too late. Medications such as Vioxx and procedures such as vertebroplasty for back pain are among the medical advances that turned out to be dangerous or useless. What Dr. Vinayak K. Prasad and Dr. Adam S. Cifu call medical reversal happens when doctors start using a medication, procedure, or diagnostic tool without a robust evidence base—and then stop using it when it is found not to help, or even to harm, patients. In Ending Medical Reversal, Drs. Prasad and Cifu narrate fascinating stories from every corner of medicine to explore why medical reversals occur, how they are harmful, and what can be done to avoid them. They explore the difference between medical innovations that improve care and those that only appear to be promising. They also outline a comprehensive plan to reform medical education, research funding and protocols, and the process for approving new drugs that will ensure that more of what gets done in doctors' offices and hospitals is truly effective. |
| car t-cell therapy market: The EBMT Handbook Nicolaus Kröger, Mohamad Mohty, Carlo Dufour, 2020-10-08 This Open Access edition of the European Society for Blood and Marrow Transplantation (EBMT) handbook addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy. Consisting of 93 chapters, it has been written by 175 leading experts in the field. Discussing all types of stem cell and bone marrow transplantation, including haplo-identical stem cell and cord blood transplantation, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies. This book provides an unparalleled description of current practices to enhance readers' knowledge and practice skills. This work was published by Saint Philip Street Press pursuant to a Creative Commons license permitting commercial use. All rights not granted by the work's license are retained by the author or authors. |
| car t-cell therapy market: Chimeric Antigen Receptor T Cells Kamilla Swiech, Kelen Cristina Ribeiro Malmegrim, Virgínia Picanço-Castro, 2020-11-24 This volume provides comprehensive methods from expert scientists working in the Chimeric Antigen Receptor T Cell (CAR-T Cell) field. Chapters guide readers through the state-of-art of CAR-T cell technology, CAR design and vector production, CAR-T cell generation and manufacturing, CAR-T cell characterization, and quality control. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Chimeric Antigen Receptor T Cells: Development and Production aims to be useful in the production of CAR-T cells, especially for therapeutic purposes. |
| car t-cell therapy market: Conscious Capitalism, With a New Preface by the Authors John Mackey, Rajendra Sisodia, 2014-01-07 The bestselling book, now with a new preface by the authors At once a bold defense and reimagining of capitalism and a blueprint for a new system for doing business, Conscious Capitalism is for anyone hoping to build a more cooperative, humane, and positive future. Whole Foods Market cofounder John Mackey and professor and Conscious Capitalism, Inc. cofounder Raj Sisodia argue that both business and capitalism are inherently good, and they use some of today’s best-known and most successful companies to illustrate their point. From Southwest Airlines, UPS, and Tata to Costco, Panera, Google, the Container Store, and Amazon, today’s organizations are creating value for all stakeholders—including customers, employees, suppliers, investors, society, and the environment. Read this book and you’ll better understand how four specific tenets—higher purpose, stakeholder integration, conscious leadership, and conscious culture and management—can help build strong businesses, move capitalism closer to its highest potential, and foster a more positive environment for all of us. |
| car t-cell therapy market: Economic Dimensions of Personalized and Precision Medicine Ernst R. Berndt, Dana P. Goldman, John Rowe, 2019-04-22 Personalized and precision medicine (PPM)—the targeting of therapies according to an individual’s genetic, environmental, or lifestyle characteristics—is becoming an increasingly important approach in health care treatment and prevention. The advancement of PPM is a challenge in traditional clinical, reimbursement, and regulatory landscapes because it is costly to develop and introduces a wide range of scientific, clinical, ethical, and socioeconomic issues. PPM raises a multitude of economic issues, including how information on accurate diagnosis and treatment success will be disseminated and who will bear the cost; changes to physician training to incorporate genetics, probability and statistics, and economic considerations; questions about whether the benefits of PPM will be confined to developed countries or will diffuse to emerging economies with less developed health care systems; the effects of patient heterogeneity on cost-effectiveness analysis; and opportunities for PPM’s growth beyond treatment of acute illness, such as prevention and reversal of chronic conditions. This volume explores the intersection of the scientific, clinical, and economic factors affecting the development of PPM, including its effects on the drug pipeline, on reimbursement of PPM diagnostics and treatments, and on funding of the requisite underlying research; and it examines recent empirical applications of PPM. |
| car t-cell therapy market: Advances In Pharmaceutical Cell Therapy: Principles Of Cell-based Biopharmaceuticals Christine Guenther, Andrea Josefine Hauser, Ralf Huss, 2015-09-23 This textbook is a comprehensive overview of the development of cell-based biopharmaceuticals. Beginning with the underlying biology of stem cell and cell-based products, it traces the long and complex journey from preclinical concept to initiation of a pivotal clinical trial and the potential business model behind it.The book also takes into consideration the different regulatory landscapes and their continuous evolution in Europe, North America and other parts of the world. The authors describe a path to manufacture a clinical grade therapeutic that passes all necessary quality measures as a robust and marketable product including an outlook on next generation products and innovative strategies.This reference book is a must-have guide for any professional already active in biopharmaceuticals and anyone interested in getting involved in a scientific, medical or business capacity. |
| car t-cell therapy market: The Role of NIH in Drug Development Innovation and Its Impact on Patient Access National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Board on Health Care Services, 2020-01-27 To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop. |
| car t-cell therapy market: From Research to Reality The Expert Panel on the Approval and Use of Somatic Gene Therapies in Canada, 2020-11-05 From Research to Reality describes the stages involved in the approval and use of gene therapies in Canada, and examines challenges associated with regulatory oversight, manufacturing, access, and affordability, and identifies promising approaches to address them. |
| car t-cell therapy market: Stem Cell Therapy: A Rising Tide: How Stem Cells Are Disrupting Medicine and Transforming Lives Neil H. Riordan, 2017-06-20 Stem cells are the repair cells of your body. When there aren't enough of them, or they aren't working properly, chronic diseases can manifest and persist. From industry leaders, sport stars, and Hollywood icons to thousands of everyday, ordinary people, stem cell therapy has helped when standard medicine failed. Many of them had lost hope. These are their stories. Neil H Riordan, author of MSC: Clinical Evidence Leading Medicine's Next Frontier, the definitive textbook on clinical stem cell therapy, brings you an easy-to-read book about how and why stem cells work, and why they're the wave of the future. |
| car t-cell therapy market: Natural Killer Cells Srinivas S. Somanchi, 2016-05-13 This volume contains collection of Natural Killer Cell methodologies relevant for both basic and translational research. These methodologies present new developments in the natural killer (NK) cell field, such as understanding the influence of NK cells metabolism on its function, identifying complexity of NK cell subsets through mass cytometry, and determining the emergence of memory NK cells in murine model of MCMV infection. Methods that study NK cell migration and cytotoxicity through endpoint analysis or live single cell imaging are also discussed. Chapters also describe methods pertaining to translational application of NK cells, such as ex vivo expansion of NK cells on K562 cell lines genetically modified to express either membrane bound IL-15 or membrane bound IL-21, large scale NK cell culture, current techniques for engineering NK cells to express chimeric antigen receptors or chemokine receptors using retroviral vectors, electroporation of mRNA, and the natural phenomenon of trogocytosis. Written in the highly successful Methods in Molecular Biology series format, these chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting edge and thorough, Natural Killer Cells: Methods and Protocols is a valuable resource for researchers who not only want to understand mechanisms that govern NK cell behavior and diversity, but also for those who want to understand how to systematically evaluate NK cells for adoptive immunotherapy applications. |
| car t-cell therapy market: Gene and Cell Therapy Nancy Smyth Templeton, 2003-12-17 This reference is completely revised and expanded to reflect the most critical studies, controversies, and technologies impacting the medical field, including probing research on lentivirus, gutless adenovirus, bacterial and baculovirus vectors, retargeted viral vectors, in vivo electroporation, in vitro and in vivo gene detection systems, and all inducible gene expression systems. Scrutinizing every tool, technology, and issue impacting the future of gene and cell research, it is specifically written and organized for laymen, scholars, and specialists from varying backgrounds and disciplines to understand the current status of gene and cell therapy and anticipate future developments in the field. |
| car t-cell therapy market: Immunotherapy of Hepatocellular Carcinoma Tim F. Greten, 2018-08-22 In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients. |
| car t-cell therapy market: Targeted Therapies in Breast Cancer Gw Sledge, George W. Sledge (Jr.), 2012-06 This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management. |
| car t-cell therapy market: Genetic Modification Therapies Clinical Applications BCC Research, 2018-08 |
| car t-cell therapy market: Second Generation Cell and Gene-Based Therapies Alain Vertes, Nathan J. Dowden, Devyn Smith, Nasib Qureshi, 2020-02-07 Second Generation Cell and Gene-Based Therapies: Biological Advances, Clinical Outcomes, and Strategies for Capitalisation serves as the only volume to the market to bridge basic science, clinical therapy, technology development, and business in the field of cellular therapy/cytotherapy. After more than two decades of painstaking fundamental research, the concept of therapeutic cells (stem cells, genes, etc.), beyond the concept of vaccines, is reaching clinical trial, with mounting confidence in the safety and efficacy of these products. Nonetheless, numerous incremental technical advances remain to be achieved. Thus, this volume highlights the possible R&D paths, which will ultimately facilitate clinical delivery of cutting edge curative products.The next waves of innovation are reviewed in depth for hematopoietic stem cells, mesenchymal stem cells, tissue engineering, CAR-T cells, and cells of the immune system, as well as for enabling technologies such as gene and genome editing. Additionally, deep dives in product fundamentals, history of science, pathobiology of diseases, scientific and technological bases, and financing and technology adoption constraints are taken to unravel what will shape the cytotherapy industry to the horizon 2025 and beyond. The outcome is not simply a scientific book, but a global perspective on the nascent field combining science, business, and strategic fundamentals. - Helps readers learn about the most current trends in cell-based therapy, their overall effectiveness from a clinical prospective, and how the industry is moving therapies forward for capitalization - Perspectives section at the end of each chapter summarizes key learnings, hypotheses, and objectives highlighted and combines scientific and business insights - Edited and authored by scientists representing both basic and clinical research and industry, presenting a complete story of the current state and future promise of cellular therapies |
| car t-cell therapy market: The molecular landscape and promising therapeutic targets in aggressive B-cell non-Hodgkin lymphomas Niklas Gebauer, Hanno Maximilian Witte, Axel Künstner, Francesco Piazza, Gaël Roué, 2023-09-29 |
| car t-cell therapy market: Engineered Targeted Cancer Immunotherapies Massimo Fantini, Roberto Bei, 2022-08-01 |
Driving the next wave of innovation in CAR T-cell therapies
Unlocking the full potential of CAR T-cell therapies requires investment in four areas. therapies have demonstrated the potential to disrupt cancer care—but its application is currently limited …
The next-generation CAR-T therapy landscape - Nature
Since the introduction of Kymriah in 2017, the CAR-T market has grown to $1.7 billion in 2021 and is expected to reach $7.5 billion in sales (~35% compound annual growth rate) as existing...
Global CAR-T Cell Therapy Market Market Size, Forecasts, …
Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials,& Trends, 2025 | BIOINFORMANT _____ 4 TABLE OF CONTENTS 1. REPORT OVERVIEW..... 17
The next S curve of cell therapy: Opportunities across the …
Non-comprehensive market scan of chimeric antigen receptor (CAR) T-cell therapies for oncology indications currently in Phase II or more advanced in the US 1. LBCL: Large B-cell lymphoma
White Paper Private Market Opportunity for CAR T-cell …
Chimeric antigen receptor (CAR) T-cell therapy is a next generation therapy which currently treats patients with certain haematological cancers including acute lymphoblastic leukaemia (ALL), …
The Economics of CAR T-Cell Therapy - accc-cancer.org
Chimeric antigen receptor (CAR) T-cell therapy is a rapidly growing area of oncology that has been transforming cancer care since its initial approval for acute lymphoblastic leukemia in …
CAR-T Cell Therapy Market Analysis - targo-consulting.com
The global CAR-T Cell therapy market was estimated at US$ 167.9 million in 2018 and is expected to witness a CAGR of 46.1% until 20281. The market is still very small since only 2 …
Chimeric antigen receptor–T cell therapy manufacturing: …
This article focuses specifically on CAR-T cell therapies due to their new arrival in the market and acute need for a commercially sustainable manufacturing and supply chain model. Current …
Cost-effectiveness analyses (CEAs) of CAR-T therapies over …
The Chimeric antigen receptor (CAR) T-cell therapy is a personalized gene therapy that consists in collecting T cells from the patient’sown blood, via a process known as apheresis, and to …
The next-generation CAR-T therapy landscape - Nature
antigen receptor (CAR)-T cell therapies are becoming established as an important treatment modality for cancer. Following the pioneering approval of the CD19-targeted CAR-T therapy...
Landscape of cancer cell therapies: trends and real-world data …
chimeric antigen receptor (CAR)-T cell therapies have gained approval, the last one of which, ciltacabtagene autoleucel (Carvykti), was approved in February 2022. The cell therapy field...
Navigating the CAR T-cell Therapy Landscape to Develop …
Client was preparing for the US launch of a CAR T-cell therapy into a new, rapidly evolving, and highly competitive market, with the following project objectives: Understand the market access …
Counterpoint Global Insights CAR-T Therapy - Morgan Stanley
uses CAR-T cells that are manufactured ahead of time from healthy donors rather than the bespoke manufacturing of the cells of an ill cancer patient. This approach is known as …
Global CAR-T Cell Therapy Market Market Size, Forecasts, …
Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends, 2023 | BioInformant TABLE OF CONTENTS 1. REPORT OVERVIEW 19 1.1 Statement of the Report …
CAR-T Therapy - ECPC
CAR-T cells are genetically modified T-cells which express a CAR corresponding to a specific tumour antigen, thus making it able to recognize and target tumour cells exclusively, unlike …
Cell and Gene Therapy Hot Buttons Series - IQVIA
The global market for CAR-T therapy is estimated to grow from 1.5 billion USD in 2021 to reach 7.6 billion USD by 2026, at a compound annual growth rate (CAGR) of 39.1% during 2021 …
Reimbursement of CAR-T cell therapies in Europe: Key …
CAR-Ts are genetically modified T-cells targeting cancer antigens. These therapies have revolutionised haematologic cancer treatment by demonstrating outstanding potential for curing …
Consideration of a Sustainable Cell and Gene Therapy …
Apr 3, 2020 · CAR-T cell therapy is a type of treatment in which T cells (a type of immune cell in the blood) are first collected from the patient’s body and processed. The processing mainly …
CAR-T Cell Therapy Market Trends - Fortune Business Insights
May 19, 2025 · CAR-T cell therapy market size is projected to grow from $6.37 billion in 2024 to USD 16.35 billion by 2032, exhibiting a CAGR of 12.5% during 2023-2032.
CAR T-cell Therapy Market Summary - Grand View Research
The global CAR T-cell therapy market size was estimated at USD 4.65 billion in 2024 and is estimated to reach USD 15.97 billion by 2030, growing at a CAGR of 22.2% from 2025 to 2030.
CAR T-cell Therapy Market Size, Growth Outlook 2025 - 2034
The global CAR T-cell therapy market size was valued at USD 4.3 billion in 2024 and is estimated to grow at 30.5% CAGR from 2025 to 2034, driven by growing cases of cancer malignancies …
CAR T-Cell Therapies Market Size Skyrockets 29.8% CAGR by 2034
May 12, 2025 · CAR-T therapy is a type of cell therapy in which immune T cells are modified genetically to attack the cancer cells by means of injecting chimeric antigen receptors. It is also …
CAR T-Cell Therapy Market Size to Hit USD 128.55 Billion by 2034
Mar 28, 2025 · The global CAR T-cell therapy market size was calculated at USD 10.39 billion in 2024 and is projected to surpass around USD 128.55 billion by 2034 with a solid CAGR of …
CAR T-Cell Therapy Market Size, Share, Growth [2033] - Astute …
The global CAR T-cell therapy market is set for substantial expansion, projected to exceed USD 27.5 billion by 2033, up from USD 2.7 billion in 2025, reflecting a robust CAGR of 26.2% from …
CAR-T Cell Therapies Market Size, Share | CAGR Of 13.8%
Market Growth: Expected to surge from USD 2.8 Billion in 2023 to USD 10.2 Billion by 2033, exhibiting a notable 13.8% CAGR during 2024-2033. Drug Type Dominance: Axicabtagene …
CAR-T Cell Therapy Market Forecast Report, 2034 - Polaris
The CAR-T cell therapy market size was valued at USD 7.31 billion in 2024. The market is projected to grow from USD 11.25 billion in 2025 to USD 188.84 billion by 2034, exhibiting a …
CAR T-Cell Therapy Market Size, Share, Report | 2034
Dec 18, 2024 · The global CAR T-cell therapy market size was valued at USD 2.50 Billion in 2024 and it is anticipated to grow at a CAGR of 15.20% during the forecast period of 2025-2034.
CAR T cell Therapy Market Size & Share, 2033 - Market Data …
The global CAR T cell therapy market is expected to reach USD 8.18 billion by 2033 from USD 2.97 billion in 2025, growing at 13.5% CAGR.
CAR T-Cell Therapy Market | Size, Trends, Opportunities
Global CAR T-Cell Therapy Market Forecast. The CAR T-Cell therapy market is projected to reach a size of US$23.4 Bn by 2031, showing significant growth from the US$5.6 Bn achieved …
CAR T-cell Therapy Market is Projected to row 35-40% by 2029
Global CAR T-cell Therapy Market is expected to grow 35-40% from 2024 to 2029. Key drivers include advancements in CAR T-cell Therapy, cancer prevalence, and strategic partnerships, …
Global CAR T-Cell Therapy Market Size | Mordor Intelligence
The Global CAR T-Cell Therapy Market size is estimated at USD 4.20 billion in 2025, and is expected to reach USD 9.95 billion by 2030, at a CAGR of 13.45% during the forecast period …
CAR T-Cell Therapy Market Size | Companies - Nova One Advisor
The global CAR T-Cell therapy market size was valued at USD 9.11 billion in 2023 and is projected to surpass around USD 127.53 billion by 2033, registering a CAGR of 30.2% over the …
CAR T-Cell Therapy Market Size, Competitors & Forecast
CAR T-cell therapy leverages the body’s own immune system to target and eliminate cancer cells. CAR-T cell therapies have been demonstrated to enable complete disease remission, omitting …
CAR T-cell Therapy Market Size, Share and Forecast 2030
The global CAR T-cell therapy market size was evaluated at $378.49 million in 2022 and is predicted to hit $2,406.39 million by the end of 2030 with a CAGR of nearly 26.20% between …
Global market size of CAR T-cell therapies 2022 vs 2030 - Statista
Feb 21, 2025 · From 2022 to 2030, the global market for CAR T-cell therapies is expected to grow from approximately 2.3 billion U.S. dollars to 10.3 billion U.S. dollars. with an estimated...
CAR T Cell Therapy Market To Reach USD 39.9 Billion By 2032, …
May 7, 2024 · The CAR T Cell Therapy market size was valued at USD 4.5 Billion in 2023 and is expected to reach a market size of USD 39.9 Billion by 2032 at a CAGR of 27.5%. Fort Collins, …
CAR T Cell Therapy Market Projected to Witness Massive
4 days ago · According to a recent report by Coherent Market Insights, the global Car T Cell Therapy Market is estimated to be valued at USD 3.99 Bn in 2025 and is expected to reach …
T-cell Therapy Market Size & Share Analysis Report, 2030
CAR T-cell therapy dominated the T-cell therapy market with a share of 95.66% in 2022. This is attributable to the recent approval of Kymriah & Yescarta that has accelerated R&D …
How CAR T Cell Therapy is Pushing the Boundaries of Cancer Treatment
Aug 21, 2024 · Another investigative approach involves how stem cells might help produce a boundless source of off-the-shelf CAR T cells. CRI Lloyd J. Old STAR Paul Beavis, PhD, …
CAR T-cell Therapy Market Size To Reach $15.97Bn By 2030
The global CAR T-cell therapy market size is estimated to reach USD 15.97 billion by 2030, expanding at a CAGR of 22.2% from 2025 to 2030, according to a new report by Grand View …
Gilead's CAR-T cell therapy shows promise in deadly brain cancer
Jun 1, 2025 · A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain …
Cardinal Health releases new report on the cell and gene therapy ...
May 7, 2025 · Cardinal Health Market SM. The legacy Cardinal.com Medical Ordering site has been replaced with Cardinal Health Market SM, ... of more than 100 healthcare providers as …
CAR T-Cell Therapy: New Advances Move On Past Setbacks
Breyanzi is a CAR T therapy for various forms of non-Hodgkin lymphoma. “Breyanzi has demonstrated efficacy and manageable safety in five cancer types, the most of any CD19 …
Johnson & Johnson’s dual-targeting CAR T-cell therapy shows …
3 days ago · These data are advancing our pipeline of CAR T therapies for the treatment of B-cell malignancies and are an extension of our worldwide collaboration and licensing agreement …
Regulatory T cell therapies to treat autoimmune diseases and
Jun 2, 2025 · Regulatory T cell therapies have shown promise for treating autoimmune diseases and aiding transplantation. We summarize a recent NIAID/HESI-sponsored workshop that …
Frontiers | Cytokine release syndrome and CAR T Cell therapy ...
6 days ago · Introduction. CAR T cell therapy has been shown to be highly effective in many hematological cancers, especially in B cell lymphomas, B cell acute lymphoblastic leukemia, …
J&J CAR-T therapy for B-cell lymphoma shows promise in phase 1
2 days ago · Naeblys. Phase 1b data on Johnson and Johnson's experimental CAR T-cell therapy JNJ-4496 found a high complete response rate at the recommended phase 2 dose in patients …
